Libtayo (cemiplimab) is an intravenous programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
iStent inject Trabecular Micro-Bypass Stent (Glaukos Corp.) in Combination with Cataract Surgery for Management of Open-Angle Glaucoma
Health Problem: Glaucoma is a disease of the optic nerve characterized by loss of retinal ganglion cells; remodeling of the lamina cribrosa; structural changes to the nerve; elevated intraocular pressure (IOP); and progressive, irreversible loss of vision leading to blindness. Open-angle glaucoma (OAG) is associated with partial blockage of t…
Dextenza (Dexamethasone Ophthalmic Insert)
Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain and inflammation after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization…
Dextenza (Dexamethasone Ophthalmic Insert)
Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain and inflammation after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization…
Zulresso (Brexanolone) for Postpartum Depression
Zulresso (brexanolone) is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA) receptors. Plasma allopregnanolone concentrations rise in concert with progesterone…
Zulresso (Brexanolone) for Postpartum Depression
Zulresso (brexanolone) is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA) receptors. Plasma allopregnanolone concentrations rise in concert with progesterone…
Celiprolol (Proposed Name: Edsivo) for Vascular Ehlers-Danlos Syndrome
Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing vascular tone and smooth muscle. Celiprolol is believed to provide clinical benefit for people with vascular EDS b…
Celiprolol (Proposed Name: Edsivo) for Vascular Ehlers-Danlos Syndrome
Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing vascular tone and smooth muscle. Celiprolol is believed to provide clinical benefit for people with vascular EDS b…
Genetic Testing in Patients with or Suspected of Congenital and/or Prelingual Nonsyndromic Hearing Loss
This report evaluates the clinical utility of genetic testing in patients with or suspected of congenital and/or prelingual nonsyndromic hearing loss.
Genetic Testing in Patients with or Suspected of Congenital and/or Prelingual Nonsyndromic Hearing Loss
This report evaluates the clinical utility of genetic testing in patients with or suspected of congenital and/or prelingual nonsyndromic hearing loss.